MYH11 Suppresses Colorectal Cancer Progression by Inhibiting Epithelial-Mesenchymal Transition via ZEB1 Regulation

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Colorectal cancer (CRC) presents significant mortality due to metastasis and treatment resistance.
• Understanding the molecular mechanisms driving CRC progression is critical for developing targeted therapies.

Purpose of the Study:

• Investigate the role of Myosin Heavy Chain 11 (MYH11) in CRC.
• Determine MYH11's impact on epithelial-mesenchymal transition (EMT) and cancer cell behavior.
• Explore the regulatory relationship between MYH11 and the EMT transcription factor zinc finger E-box binding homeobox 1 (ZEB1).

Main Methods:

• Differential gene expression analysis of CRC datasets (GSE123390, TCGA-READ).
• Protein-protein interaction (PPI) analysis to identify hub genes.
• In vitro experiments to assess the functional effects of MYH11 and ZEB1 on CRC cell behavior.
• Western blotting to analyze EMT marker expression.

Main Results:

• MYH11 was significantly downregulated in CRC tissues compared to normal tissues.
• MYH11 overexpression suppressed CRC cell proliferation, migration, and invasion.
• MYH11 inhibited EMT by increasing E-cadherin and decreasing ZEB1, vimentin, and N-cadherin.
• ZEB1 overexpression promoted EMT and enhanced CRC cell aggressiveness.
• Co-overexpression of MYH11 and ZEB1 partially reversed MYH11's inhibitory effects, indicating ZEB1 mediates MYH11's action.

Conclusions:

• MYH11 acts as a tumor suppressor in CRC by inhibiting EMT and invasion.
• ZEB1 antagonizes the suppressive effects of MYH11, suggesting a key regulatory axis in CRC.
• MYH11 holds potential as a therapeutic target for CRC treatment.